ClinicalTrials.Veeva

Menu

Prospective Cohort for Adult Hemophagocytosis

Samsung Medical Center logo

Samsung Medical Center

Status

Enrolling

Conditions

Hemophagocytic Lymphohistiocytoses

Treatments

Drug: Etoposide
Drug: Steroids

Study type

Observational

Funder types

Other

Identifiers

NCT03117010
2016-08-117

Details and patient eligibility

About

This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.

Full description

Study process is as follows.

  1. Informed consent for subjects fulfilling the inclusion criteria.

  2. Laboratory evaluation will be done for subjects according to the following diagnostic criteria.

    • Diagnosis will be established if one of either 1 or 2 below is fulfilled

      1. A molecular diagnosis consistent with HLH
      2. Diagnostic criteria for HLH fulfilled (5 out of 8 criteria below)
    • fever ≥ 38.5'C for ≥ 7 days

    • splenomegaly ≥ 3 finger breadth below left subcostal margin

    • cytopenias affecting ≥2 of 3 lineages in peripheral blood (Hemoglobin < 9 g/L, Platelets < 100 × 109/L, Absolute neutrophil count < 1.0 × 109/L)

    • Hypertriglyceridemia and/or hypofibrinogenemia: Fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L

    • Hemophagocytosis in bone marrow or spleen or lymph node

    • Low or absent NK-cell activity (according to local laboratory reference)

    • Ferritin ≥ 500 mcg/L

    • Soluble CD25 (sIL-2 receptor) ≥ 2,400 U/mL

Enrollment

81 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Subjects should fulfill the following criteria

    1. Subjects should have at least one of the following problems

      1. Presence of hemophagocytosis in tissue or bone marrow
      2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
    2. Age > 18 years

    3. Written informed consents

      Exclusion Criteria:

  • Subjects cannot satisfy the inclusion criteria

Trial design

81 participants in 1 patient group

Hemophagocytosis
Description:
Subjects should fulfill the following criteria 1. Subjects should have at least one of the following problems 1. Presence of hemophagocytosis in tissue or bone marrow 2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria 2. Age \> 18 years 3. Written informed consents Subjects receive steroids and etoposide
Treatment:
Drug: Steroids
Drug: Etoposide

Trial contacts and locations

1

Loading...

Central trial contact

Seok Jin Kim, MD, PhD; Silvia Park, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems